238 results about "Myocardial fibrosis" patented technology

The invention relates to compounds for selectively inhibiting human corticosteroid synthases CYP1 1 B1 and CYP1 1 B2, and to the production and use thereof for treating hypercortisolism, diabetes mellitus, hyperaldosteronism, cardiac insufficiency, myocardial fibrosis, depression, age-related cognitive decline and metabolic syndrome.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present invention relates generally to the field of prophylaxis and therapy for inflammatory and / or fibrotic diseases which include responses to injuries. In particular, the present invention is related to agents that can bind or complex copper such as thiomolybdate, and to the use of these agents in the prevention and treatment of inflammatory and / or fibrotic diseases. Exemplary thiomolybdates include mono-, di-, tri- and tetrathiomolybdate; these agents are administered to patients to prevent and / or treat inflammatory and / or fibrotic diseases, such as pulmonary disease including pulmonary fibrosis and acute respiratory distress syndrome, liver disease including liver cirrhosis and hepatitis C, kidney disease including renal interstitial fibrosis, scleroderma, cystic fibrosis, pancreatic fibrosis, keloid, secondary fibrosis in the gastrointestinal tract, hypertrophic burn scars, myocardial fibrosis, Alzheimer's disease, retinal detachment inflammation and / or fibrosis resulting after surgery, and graft versus host and host versus graft rejections.

The invention discloses a microRNA-328 and the application of antisense nucleotide thereof for diagnosing and controlling heart diseases; in the invention, a plurality of experiments prove that the microRNA-328 is changed and has pathopoiesia function in heavy heart diseases (atrial fibrillation, ischemia-reperfusion or myocardial fibrosis), and the antisense nucleotide AMO-328 of the microRNA-328has prevention and cure functions to the heart diseases, the microRNA-328 is used as a novel drug effect target spot, so as to finally determine and detect that the peripheral blood microRNA-328 canbe used as a novel biological marker which is used for diagnosing and preventing the heart diseases; in addition, the peripheral blood microRNA-328 expression level of a patient can be detected through fluorescent quantitative PCR and the nanometer microballoon technology enhanced by silver staining, so as to be used for diagnosing and preventing the heart diseases such as atrial fibrillation, long QT syndrome, ischemia-reperfusion or myocardial fibrosis and the like.

The present invention is concerned with composition and methods for treatment of certain cardiovascular conditions. In particular it is concerned with prophylactic or therapeutic treatment of myocardial fibrosis or associated conditions by administering compositions comprising vasoactive intestinal peptide (VIP) and / or active fragments) thereof.

An application of an invented medicinal composition in preparing the medicines for treating primary hypertension and protecting heart and kidney is disclosed.

The invention provides a bioconjugates comprising a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein and a half-life extending moiety wherein the peptide and the half-life extending moiety are covalently linked or fuse, optionally via a linker. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the bioconjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention relates to a medicinal composition containing an IncRNA inhibitor and an application thereof. The medicinal composition comprises the IncRNA inhibitor and a vector, wherein the nucleotide sequence of the IncRNA inhibitor is 5'-CAGUGAGGUAGUCUCACAA-3'; the vector is one or more of chitosan, cholesterol, nano particles and lipidosome. The content of the IncRNA inhibitor in the medicinal composition is 0.5-1g. The medicinal composition is used for treating and preventing myocardial infarction, myocardial ischemial injury and myocardial fibrosis. The medicinal composition has the advantages that the selected materials are scientific and reasonable, the preparation process is simple, the medicinal action is obvious, the use range is wide, the safe and reliable effects are achieved and the medicinal composition is friendly to the application environment.

The invention discloses a pure traditional Chinese medicine preparation for treating dilated cardiomyopathy, which is prepared from astragali, radix salviae miltiorrhizae, red peony root, root-bark of peony, radix rehmanniae and the like as raw materials by steps of decocting twice, decocting filtrate, concentrating, granulating and packing in composite membrane bags. Shown by pharmacodynamic experiments of animals and clinical statistical results of patients, the pure traditional Chinese medicine preparation for treating dilated cardiomyopathy has the efficacies of supplementing qi, activating blood circulation, detoxifying and tranquilizing mind, and can eliminate the symptoms of chest distress, short breath, palpitation, edema, vexation, dark red tongue, yellow fur of tongue, thready rapid pulse, intermittent pulse and the like caused by deficiency of qi, blood stasis, toxic heat and heart disturbance due to dilated cardiomyopathy. The pure traditional Chinese medicine preparation can effectively resist myocardial fibrosis, improves the anoxia tolerance ability of myocardial cells and can be safely taken for a long time without toxic or side effect, the total effective rate in treating the dilated cardiomyopathy is 96.6%, and the curative effect is obviously better than that of conventional simple treatment of Western medicine.

The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.

The invention discloses an application of miR-378 in the preparation of a medicine or a kit for preventing or treating cardiac hypertrophy and myocardial fibrosis, and further discloses an application of the miR-378 as a heart failure biomarker. The miR-378 has a protection effect of resisting against myocardial remodeling on the heart through inhibiting cardiac hypertrophy and myocardial fibrosis, has potential prevention and treatment values on multiple heart diseases. The miR-378 is conducive to auxiliary diagnosis of the heart failure, meanwhile, due to expression difference in the blood of patients with mild and severe heart failures, the miR-378 is conducive to reflection of the disease state of the patients with heart failures, and provides a support for clinical doctors to quickly and accurately master the situations of the patients and timely take more personalized prevention and treatment schemes.

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention relates to a piRNA antisense nucleotide pharmaceutical composition and an application thereof. The pharmaceutical composition comprises a piRNA antisense nucleotide and a carrier, wherein the sequence of the piRNA antisense nucleotide is 5'-CCUUGGCACAUGCGCAGAUUAUUUGUUUA-3'; and the carrier is one or more of chitosan, cholesterol, nano-particles and lipidosome. The pharmaceutical composition is applied to treatment and prevention of myocardial infarction, myocardial ischemial injury and myocardial fibrosis, and is scientific and reasonable in raw material, simple in preparation technology, obvious in medicine effect, wide in application range, safe, reliable and friendly to application environment.

The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1):X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention discloses circRNA CHIF nucleotide and a pharmaceutical composition comprising the circRNA CHIF nucleotide. The pharmaceutical composition comprises the circRNA CHIF nucleotide, an auxiliary, and a viral vector or an embedding vector, the embedding vector is cholesterol, nanoparticles or lipidosome, preferably lipidosome, the viral vector is one or more of adenovirus vector, lentiviral vector and retroviral vector, preferably adenovirus vector, and the auxiliary is one or more of mannitol, phosphate buffer solution and normal saline, preferably phosphate buffer solution, the circRNA MNCR viral vector is 1016 PFU in infectivity titer, and a mass ratio of the circRNA CHIF nucleotide to the lipidosome is 1:1.25; a mass ratio of the viral vector or embedding vector to the auxiliaries is 1:200. The pharmaceutical composition is used for preventing and treating cardiac hypertrophy, cardiac fibrosis, coronary heart disease and heart failure, has reasonable formula, is simple to manufacture, has significant therapeutic effect, is widely applicable and is friendly to service environments.

The invention relates to the technical field of medicines, and particularly relates to cryptotanshinone for preventing and treating pulmonary fibrosis and an application thereof. The cryptotanshinone (I) is quinone diterpene extracted from the root part of salviae miltiorrhizae; the modern pharmacological research shows that the cryptotanshinone has a bacteriostatic effect, an anti-inflammatory effect and a hormone-like pharmacologic effect, and is clinically used for treating myocardial fibrosis, lung acute injury and arthritis, can be used for preventing and / or treating a pulmonary fibrosis disease, can also be used for preparing medicines for reducing body weight of a pulmonary fibrosis rat, a lung coefficient and the content of hydroxyproline in tissue and can be used for preparing the medicines for reducing the content of IL-1beta, IL-6 and TNF-alpha in a bronchoalveolar lavage liquid and the medicines of effecting the pathogeny structure of pulmonary fibrosis tissue of the rat. The formula (I) is as shown in the specification.

The invention provides application of LncRNA (long non-coding RNA) and a medicine using the same, and relates to the technical field of medical biology. The LncRNA provided by the invention has the nucleotide sequence shown as SEQ ID NO.1, and experiments find that the expression of the LncRNA is significantly decreased in cardiomyocytes suffering from cell death and heart tissues and the LncRNA has a protective effect on myocardial infarction and myocardial fibrosis, so that through overexpression of the LncRNA, the purposes of preventing and / or treating heart diseases can be achieved. The invention further provides the medicine comprising the LncRNA. The medicine can achieve the purposes of preventing and / or treating the heart diseases through the overexpression of the LncRNA; meanwhile,the medicine is obvious in therapeutic effect, wide in application range and friendly to using environment.

The invention relates to the novel use of osthole, in particular to the application of the osthole in the preparation of a medicament for preventing and treating myocardial fibrosis, and in particular discloses a medicinal composition for preventing and treating the myocardial fibrosis. The medicament for preventing and treating the myocardial fibrosis takes the osthole as an active constituent, also comprises one or more universal medicinal auxiliary components and can be made into tablets, capsules, medicinal granules, drops, granules or injection by adding the universal medicinal auxiliary components into the over 95 mass percent osthole. In the invention, as the osthole is applied to the preparation of the medicament for preventing and treating the myocardial fibrosis, the medicament has relatively stronger myocardial fibrosis resisting effect.

The present invention is concerned with composition and methods for treatment of certain cardiovascular conditions. In particular it is concerned with prophylactic or therapeutic treatment of myocardial fibrosis or associated conditions by administering compositions comprising vasoactive intestinal peptide (VIP) and / or active fragments) thereof.

The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1):X1-R-X3-X4-L-S-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, or a bioconjugate thereof, wherein X1, X3, X4, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention or bioconjugates thereof, and their therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The invention relates to compounds for selectively inhibiting human corticosteroid synthases CYP1 1 B1 and CYP1 1 B2, and to the production and use thereof for treating hypercortisolism, diabetes mellitus, hyperaldosteronism, cardiac insufficiency, myocardial fibrosis, depression, age-related cognitive decline and metabolic syndrome.

The invention relates to compounds for selectively inhibiting human corticosteroid syntheses CYP11B1 and CYP11B2, to the production thereof and to their use for treating hypercortisolism and diabetes mellitus or insufficiency of the heart and myocardial fibrosis.

The invention discloses application of PEDF gene in treating diabetic myocardial damage. According to the invention, the relationship between the PEDF gene and diabetic myocardial damage is determinedfor the first time, and PEDF gene knockout can lead to a rise in weight and blood sugar, cardiomyocyte hypertrophy, myocardial fibrosis and cardiac dysfunction. It shows that the PEDF gene's functionin diabetic myocardial damage is mainly reflected in the PEDF's effects of improving cardiomyocyte hypertrophy and myocardial fibrosis and improving cardiac function. in allusion to the above functions of the PEDF gene, the PEDF can be used as a medicine for preventing, alleviating or / and treating diabetic myocardial damage; the PEDF can be used as a drug target for screening a medicine for preventing, alleviating or / and treating diabetic myocardial damage; and the PEDF also can be used as a target gene in gene therapy for designing and preparing a medicine for preventing, alleviating or / andtreating diabetic myocardial damage and / or a biological preparation.

The invention discloses a (micro ribose nucleic acid)-874 and an application of a miRNA-874 antisense nucleotide, and in particular relates to the application of the miRNA-874 antisense nucleotide in preparing pharmaceutical compositions for treating and preventing serious heart diseases (myocardial hypertrophy and myocardial fibrosis) and the application of the miRNA-874 antisense nucleotide in preparing the pharmaceutical compositions for diagnosing or prognosing the heart diseases. The miRNA-874 antisense nucleotide can control cardiac hypertrophy and cardiomyocyte hypertrophy and also has the functions of improving a cardiac function and inhibiting cardiac structure remodeling and cardiac fibering. The miRNA-874 antisense nucleotide can be used as a novel target of drug action, has a function of controlling the myocardial hypertrophy and has an important meaning for clinically preventing and treating heart diseases of cardiac fibering, coronary heat disease, heart failure and the like which are caused by cardiomyocyte hypertrophy.

The invention discloses a pharmaceutical composition of targeting circRNA (circular Ribonucleic Acid). The pharmaceutical composition comprises MFACR-siRNA (small interfering Ribonucleic Acid) nucleotide, a pharmaceutically acceptable carrier or virus carrier and an auxiliary material; the carrier is one or more of chitosan, cholesterol, nanoparticles and liposome, preferably, the liposome; the auxiliary material is one or more of mannitol, a phosphate buffering solution and saline, preferably, the phosphate buffering solution; the content of the MFACR-siRNA is 0.8 to 1.5 micrograms; the mass ratio of the MFACR-siRNA to the liposome is 1 to 1.25; the mass ratio of the carrier to the auxiliary material is 1 to 200. The pharmaceutical composition is used for treating and preventing myocardial infarction, myocardial ischemial injury, myocardial hypertrophy and myocardial fibrosis, and is dosed in an oral administration or injection manner; the injection is intravenous injection, muscle injection, intracoronary injection or direct myocardial injection. Compared with the prior art, the selected raw materials are scientific and reasonable; a preparation process is simple and the drug action is obvious; the application range is wide, the utilization is safe and reliable and the application is environment-friendly.

The present invention provides methods and compositions for controlling cardiac fibrosis and heart remodeling in a subject via modulating the expression of one or more lncRNA associated with cardiac-specific super-enhancers (SEs).

The invention provides magnetic resonance imaging methods for detecting cardiac diseases including myocardial fibrosis. Specifically, the invention provides a magnetic resonance imaging (MRI) pulse sequence that could be used to perform magnetization transfer (MT) or chemical exchange saturation transfer (CEST) in the heart.

The invention aims at providing application of miRNA to treat or diagnose myocardial fibrosis diseases. The sequence of miRNA is shown as SEQ ID 1, SEQ ID 2, SEQ ID 3, SEQ ID 4, SEQ ID 5 or SEQ ID 6. By applying miRNA to treat myocardial fibrosis diseases, substantial effect is obtained especially when different human derived miRNA-19b sequences and non-human derived miRNA-19b sequences are mixed for application, namely a human derived miRNA-19b sequence of SEQ ID 1 or SEQ ID 2 and one or more of the non-human derived miRNA-19b sequences of SEQ ID 3, SEQ ID 4, SEQ ID 5 and SEQ ID 6 are mixed.